AMAG Pharmaceuticals Inc. (AMAG) Position Boosted by Nationwide Fund Advisors
Nationwide Fund Advisors raised its stake in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) by 162.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,762 shares of the specialty pharmaceutical company’s stock after buying an additional 36,367 shares during the period. Nationwide Fund Advisors owned about 0.17% of AMAG Pharmaceuticals worth $1,406,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of AMAG. Exane Derivatives increased its stake in shares of AMAG Pharmaceuticals by 1.4% in the second quarter. Exane Derivatives now owns 19,663 shares of the specialty pharmaceutical company’s stock worth $470,000 after buying an additional 272 shares during the period. Capstone Asset Management Co. increased its stake in shares of AMAG Pharmaceuticals by 5.1% in the second quarter. Capstone Asset Management Co. now owns 10,876 shares of the specialty pharmaceutical company’s stock worth $260,000 after buying an additional 530 shares during the period. SignalPoint Asset Management LLC increased its stake in shares of AMAG Pharmaceuticals by 6.9% in the second quarter. SignalPoint Asset Management LLC now owns 20,055 shares of the specialty pharmaceutical company’s stock worth $480,000 after buying an additional 1,288 shares during the period. Teachers Advisors Inc. increased its stake in shares of AMAG Pharmaceuticals by 0.6% in the first quarter. Teachers Advisors Inc. now owns 211,501 shares of the specialty pharmaceutical company’s stock worth $4,949,000 after buying an additional 1,303 shares during the period. Finally, Capital Fund Management S.A. increased its stake in shares of AMAG Pharmaceuticals by 8.5% in the second quarter. Capital Fund Management S.A. now owns 20,733 shares of the specialty pharmaceutical company’s stock worth $496,000 after buying an additional 1,622 shares during the period.
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) opened at 24.35 on Wednesday. The company’s 50-day moving average is $24.07 and its 200-day moving average is $23.98. AMAG Pharmaceuticals Inc. has a one year low of $17.92 and a one year high of $42.49. The firm’s market capitalization is $831.65 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The firm had revenue of $127.40 million for the quarter, compared to analysts’ expectations of $128.52 million. During the same period in the previous year, the firm earned $1.12 earnings per share. The business’s revenue was up 46.7% compared to the same quarter last year. Equities analysts forecast that AMAG Pharmaceuticals Inc. will post $5.55 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the stock. Jefferies Group dropped their target price on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Friday, August 12th. Finally, Leerink Swann restated an “outperform” rating and issued a $36.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, October 13th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. AMAG Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $36.33.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.